US.: +1-252-477-1362
UK.: +44-203-957-8553
AUS.: +61-2-4786-0457
INDIA: +91-848-285-0837
The biotech industry includes bio-pharma, bio-services, bio-agri, bio-industrials and bioinformatics. Biopharma is a rapidly growing segment that accounts for a dominant share in this sector. Advancements in biotechnology have enabled researchers to evaluate and identify target biomarkers/cell receptors to develop targeted and personalized therapies. Scientific research and technological advancements have resulted in the emergence of various personalized medicines... View more
The biotech industry includes bio-pharma, bio-services, bio-agri, bio-industrials and bioinformatics. Biopharma is a rapidly growing segment that accounts for a dominant share in this sector. Advancements in biotechnology have enabled researchers to evaluate and identify target biomarkers/cell receptors to develop targeted and personalized therapies. Scientific research and technological advancements have resulted in the emergence of various personalized medicines that are undergoing research. According to research conducted by the Personalized Medicine Coalition, 42% of all compounds and 73% of oncology compounds in the pipeline possess the potential to be personalized medicine. Moreover, according to this study, it is expected that companies will increase their investment in R&D of personalized medicines by 1/3rd over the following five years. The study found that over 20% of drugs approved in 2014 were personalized medicines.
The biotechnology sector has witnessed some disruptive innovations such as gene and cell therapies, immunotherapy, and antibody drug conjugates. Advancement in stem cell therapy is resulting in effective treatment therapies for chronic conditions, organ growth and repair and disease prevention.
Key Challenges
Biotech products have extensive application in oncology and autoimmune disease treatment. However, the cost of these drugs is high owing to extensive research and trials that need to be carried out for the same. Therefore, there is constant pressure to reduce price and increase accessibility, especially in emerging economies. In the U.S., companies are facing reimbursement issues with respect to biopharmaceutical products. Besides, there are regulatory and scientific challenges faced by the sector. Scientific research for new molecules and targeted therapies is capital intensive and challenging owing to growing concern for safety of the drug.
Also, there is lack of awareness about personalized medicine among most healthcare providers, which may hamper its adoption. Clinical adoption of biotechnology products is essential for its success. However, it significant scientific evidence and backing is required to ensure its safety.
“Translating genomic discoveries into personalized medicines entails overcoming substantial scientific, regulatory, and economic challenges, including identifying validated biomarkers, as well as developing personalized therapeutics and clinically relevant diagnostic tests.”
Opportunities
The biopharmaceutical sector offers vast lucrative growth opportunities. High efficacy and safety of biopharmaceutical products has led to a growth in their demand, Furthermore, consumers are willing to pay high prices for biopharmaceutical products compared to other conventional products. Biopharmaceutical brands have set new standards for blockbuster drugs by recording an annual average sale of over US$ 2bn. Drugs such as Humira have generated sales revenue of over US$ 10bn.
Governments in emerging economies are endorsing biosimilars as cost-effective alternatives to biotech products, which is expected to create significant growth opportunities for manufacturers of generic drugs. Therefore, cost-effectiveness and high quality are prime parameters that need to be considered while developing biosimilars. Recent and upcoming biologic patent expirations include the following:
Companies such as Teva Pharmaceuticals, Hospira, Sandoz, and Amgen are focusing on development of biosimilars and vaccines as preventive measures in addition to treatment. For instance, in 2015, Zarxio TM became the first biosimilar to be approved in the U.S. market. The EMA approved Mosquirix, a malaria vaccine, in the same year. Extensive research is currently underway to develop a dengue vaccine, which could be another breakthrough pharmaceutical product in the near future.
Conclusion
The increasing research in the biotechnology sector is expected to result in higher number of biopharmaceutical products seeking FDA approvals. Biopharmaceuticals are positioned to be promising treatment solutions that would improve patient outcomes and help with reduction of the cost of drug development.View less
Published Date : May 2024
Global microbiome sequencing service market is estimated to be valued at USD 1.97 Bn in 2024 and is expected to exhibit a CAGR of 11.1% during the forecast period (2024-2031). Microbiome sequencing involves using high-throughput sequencing technologies to study the mi... View more
Published Date : May 2024
Global clinical microbiology market is estimated to be valued at USD 4.98 Bn in 2024, and is expected to exhibit a CAGR of 5.4% during the forecast period (2024-2031). Global clinical microbiology market is witnessing strong growth due to increasing prevalence of infe... View more
Published Date : May 2024
Global cell therapy manufacturing market is estimated to be valued at USD 4.91 Bn in 2024, and is expected to exhibit a CAGR of 14.9% during the forecast period (2024-2031). Global cell therapy manufacturing market has been witnessing significant growth in the recent ... View more
Published Date : May 2024
Global genome engineering market is estimated to be valued at USD 6.71 Bn in 2024, and is expected to exhibit a CAGR of 14.5% during the forecast period (2024-2031). Genome engineering, also known as genetic engineering, is a set of technologies that enable genetic ma... View more
Published Date : May 2024
Global stem cell banking market is estimated to be valued at USD 5.67 Bn in 2024, and is expected to exhibit a CAGR of 14.5% during the forecast period (2024-2031). Stem cells are undifferentiated biological cells that are capable of differentiating into specialized c... View more
Published Date : Apr 2024
The global platelet rich plasma market is estimated to be valued at USD 550.5 Mn in 2024 and is expected to exhibit a CAGR of 12.5% during the forecast period (2024-2031). Platelet Rich Plasma (PRP) is an enriched concentration of platelets extracted from a small volu... View more
Published Date : Apr 2024
The global pharmacogenomics market is estimated to be valued at USD 17.19 Bn in 2024 and is expected to exhibit a CAGR of 11.7% during the forecast period (2024-2031). Pharmacogenomics is the branch of science that analyzes how genes affect a person's response to medi... View more
Published Date : Apr 2024
Global aptamers market is estimated to be valued at USD 7.29 Bn in 2024 and is expected to exhibit a CAGR of 17.8% during the forecast period (2024-2031). Aptamers are single stranded Deoxyribonucleic acid (DNA) or Ribonucleic acid (RNA) molecules that bind to a speci... View more
Published Date : Apr 2024
Global recombinant DNA technology market is estimated to be valued at USD 172.94 Bn in 2024 and is expected to exhibit a CAGR of 9.6% during the forecast period (2024-2031). Recombinant DNA technology is the joining together of DNA molecules from two different sources... View more
Published Date : Apr 2024
Global flow cytometry market is estimated to be valued at USD 7.52 Bn in 2024 and is expected to exhibit a CAGR of 10.8% during the forecast period (2024-2031). The global flow cytometry market has been witnessing steady growth over the past few years due to the incre... View more
Published Date : Apr 2024
The Global canine influenza vaccine market is estimated to be valued at USD 1,805.7 Mn in 2024, and is expected to exhibit a CAGR of 5.1% during the forecast period (2024-2031). Canine influenza, commonly known as dog flu, is a contagious respiratory disease caused by... View more
Published Date : Apr 2024
Global sanger sequencing market is estimated to be valued at USD 3,149.9 Mn in 2024, and is expected to exhibit a CAGR of 18.2% during the forecast period (2024-2031). Sanger sequencing, also known as chain termination or dideoxy sequencing, is a method for DNA sequen... View more
Published Date : Apr 2024
Global cell therapy market is estimated to be valued at USD 2,583.8 Mn in 2024 and is expected to exhibit a CAGR of 9.4% during the forecast period (2024-2031). Global cell therapy market is expected to witness growth substantially over the next decade due to rising p... View more
Published Date : Apr 2024
The global DNA extraction kits market is estimated to be valued at USD 1,622.1 Mn in 2024 and is expected to exhibit a CAGR of 8.1% during the forecast period (2024-2031). DNA extraction kits are essential tools used to isolate DNA from biological samples. DNA, or deo... View more
Published Date : Apr 2024
Global immunotherapy drugs market is estimated to be valued at USD 166.55 Bn in 2024 and is expected to exhibit a CAGR of 11.3% during the forecast period (2024-2031). Immunotherapy drugs utilize the body's immune system to fight cancer and other diseases. These drugs... View more
Published Date : Apr 2024
Global cold laser therapy market is estimated to be valued at USD 118.1 Mn in 2024, and is expected to exhibit a CAGR of 4.5% during the forecast period (2024-2031). Cold laser therapy, also known as low-level laser therapy (LLLT), is a form of light therapy that uses... View more
Published Date : Mar 2024
Global scaffold technology market is estimated to be valued at USD 2.05 Bn in 2024 and is expected to exhibit a CAGR of 12.5% during the forecast period (2024-2031). Scaffold technology is a vital component of tissue engineering that provides a temporary structure for... View more
Published Date : Mar 2024
The global personalized medicine market is estimated to be valued at USD 81.33 BN in 2024 and is expected to exhibit a CAGR of 9.4% during the forecast period (2024-2031). Personalized medicine aims to tailor healthcare to the individual characteristics of each patien... View more
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.